| CatalogCode: | NB110-56994 |
| ProductName: | FOXO3a Antibody |
| Product Description: | Rabbit Monoclonal anti-FOXO3a (EP1949Y) |
| Clone: | EP1949Y |
| Clonality: | Monoclonal |
| Specificity: | A synthetic peptide corresponding to residues near the N-terminus of human FOXO3a was used as an immunogen. |
| CrossReactivity: | Reacts in human. Does not react in mouse or rat. Not tested in other species. |
| Packaging: | 0.1 ml |
| Uses: | WB: 1:2000-5000IHC: 1:50-100ICC: 1:50-100 |
| Background: | Forkhead box O-class (FOXO) transcription factors are mammalian homologue of DAF-16, a known lifespan regulator of Caenorhabditis elegans. FOXO transcription factors, such as FOXO1, FOXO3a, and FOXO4, have been linked to the regulation of cell cycle, apoptosis, DNA repair, oxidative stress, and metabolism (1). FOXO proteins are proposed to be dual regulated by Akt-mediated phosphorylation and Skp2-mediated ubiquitination, which are usually initiated by growth factors and cytokines. FOXO proteins are also activated by stress, which induces gene expression that contributes to cell cycle arrest, implicating FOXO proteins as tumor suppressors (2). Specifically, FOXO3a (FKHR-L1) is a transcriptional activator for apoptosis in the absence of survival factors, such as in neural cell death triggered by oxidative stress. In the presence of survival factors like IGF-1, AKT1/PKB phosphorylates on Thr-32 and Ser-253. However, in the absence of survival factors, FOXO3a is dephospholyated and translocated to the nucleus inducing transcription of target genes and apoptosis (3). |
| Storage: | Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles. |
| Isotype: | IgG |
| Host_Name: | Rabbit |
| Buffer: | 50 mM Tris-Glycine (pH 7.4), 0.18 M NaCl, 40% Glycerol, 0.25 mM EDTA, 25 mM Citric Acid, and 0.5% BS |
| ListPrice: | 325 |
| AppSummary: | IHC, WB, ICC |
| SpeciesSummary: | Hu, Mu(-), Rt(-) |
| PackageSize: | 0.1 ml |
| GeneralRef: | 1. Burgering BM and Kops GJ Trends Biochem Sci. 27(7):352-360, 2002. 2. Huang H and Tindall DJ Future Oncol 2(1):83-89, 2006. 3. Riou C et al. JEM 204(1):79-91, 2006. |
|